Met

Burberry Hosts Guests at the Met Gala 2024 in Custom Designs by Daniel Lee

Retrieved on: 
Martedì, Maggio 7, 2024

The 2024 Met Gala took place on Monday, May 6 celebrating the Costume Institute’s new exhibition, “Sleeping Beauties: Reawakening Fashion.”

Key Points: 
  • The 2024 Met Gala took place on Monday, May 6 celebrating the Costume Institute’s new exhibition, “Sleeping Beauties: Reawakening Fashion.”
    This year’s Met Gala theme is based on J.G.
  • Chief Creative Officer, Daniel Lee, was inspired by the central motif of the story’s flora and its connection with British culture.
  • Since his first collection, flowers have been incorporated into his designs and campaigns – such as roses, daisies and daffodils.
  • Flora is a key feature in the Met Gala designs.

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Retrieved on: 
Giovedì, Aprile 25, 2024

FOSTER CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that its partner in China, Avistone Biotechnology Co. Ltd. (Avistone), received approval from the National Medical Products Administration (NMPA) of China for vebreltinib (APL-101) for the treatment of adult patients with isocitrate dehydrogenase (IDH) mutant astrocytoma (WHO Grade 4) or glioblastoma with a history of low-grade disease who have the PTPRZ1-MET fusion (ZM fusion) gene and have failed previous treatments. This supplemental New Drug Application (sNDA) approval makes vebreltinib the world’s first c-Met inhibitor approved for treatment of Central Nervous System (CNS) tumor with c-Met alteration, and follows the NMPA’s November 2023 approval of vebreltinib for the treatment of patients with Met Exon 14 skipping non-small cell lung cancer (NSCLC).

Key Points: 
  • "The NMPA’s approval of vebreltinib in gliomas is an important, first-in-class approval as it demonstrates vebreltinib’s CNS penetration ability and c-Met inhibitory activity in the tumors there," said Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics.
  • Surgery, radiation treatment, and chemotherapy are current standard treatment strategies for gliomas with poor prognoses.
  • These preliminary data support cross-region similarity of patient response to treatment with vebreltinib.
  • This collaboration enables both companies to leverage their strengths and maximize the benefit of vebreltinib worldwide.

Minted Collaborates with The Metropolitan Museum of Art on Debut Wedding Collection

Retrieved on: 
Martedì, Aprile 30, 2024

Minted , the premium design marketplace committed to empowering independent artists, today announced its debut wedding stationery collaboration with The Metropolitan Museum of Art.

Key Points: 
  • Minted , the premium design marketplace committed to empowering independent artists, today announced its debut wedding stationery collaboration with The Metropolitan Museum of Art.
  • The Minted x The Met Wedding Collection features the work of Minted artists who have reimagined iconic masterpieces from the Museum’s collection as wedding stationery suites, including save the dates, wedding invitations, and day-of stationery.
  • View the full release here: https://www.businesswire.com/news/home/20240430402829/en/
    Premium design marketplace Minted announced its debut wedding stationery collaboration with The Metropolitan Museum of Art.
  • This “Chinoiserie” wedding invitation suite was designed by Minted artist Sumak Studio and inspired by an 18th century work from the Museum collection.

Sadiq Khan on track for third term as London mayor – but nearly half of Londoners dissatisfied with performance

Retrieved on: 
Giovedì, Aprile 25, 2024

Polls have consistently shown that the incumbent mayor of London, Sadiq Khan, appears to be on track to win a third term in office at the upcoming mayoral elections on May 2.

Key Points: 
  • Polls have consistently shown that the incumbent mayor of London, Sadiq Khan, appears to be on track to win a third term in office at the upcoming mayoral elections on May 2.
  • One poll we commissioned as part of our Polling London series in October 2023 put Khan ahead of his Conservative rival, Susan Hall, by 50 points to 25 (a 25-point lead for Khan).

Low satisfaction ratings

  • Khan’s lead in the mayoral race is not built on high levels of satisfaction with his previous performance in the role.
  • Khan’s rather lacklustre approval ratings make his lead appear rather more shallow.
  • This could be due to Khan’s decision, which came into effect in August 2023, to expand the ultra low emissions zone (Ulez).
  • This helps to explain why Khan is doing better in the mayoral race than his satisfaction ratings might suggest.

Policing, crime and personal safety

  • A recent poll, commissioned by the Mile End Institute, where we are both based, and fielded by YouGov from February 12-19 2024, found that 52% of Londoners felt policing, crime and personal safety was one of the most important issues currently facing the city and its population.
  • Meanwhile 46% opted for the provision of affordable quality homes and 37% for healthcare provision in the capital.
  • The next most important issue, according to Londoners, was the affordability of public transport, which 25% of respondents highlighted.
  • Londoners’ concerns about policing, crime and personal safety are likely, at least in part, to be a reflection of their low levels of trust in the Metropolitan police service.


Farah Hussain was a Labour Party local councillor in the London Borough of Redbridge 2014-2022. Elizabeth Simon does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Retrieved on: 
Giovedì, Marzo 28, 2024

ET

Key Points: 
  • ET
    FOSTER CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) --  Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the full year ended December 31, 2023, and highlighted progress of its pipeline.
  • As a result, Apollomics believes that its current capital resources will fund planned operations through the first quarter of 2025.
  • Dr. Plunkett brings to Apollomics over 25 years of strategic and financial experience within the biopharmaceutical sector, including extensive fundraising and corporate development expertise.
  • In March 2023, the Company raised $23.7 million in a private placement in public equity (PIPE) financing, before transaction expenses.

Nalgene Outdoor Drops New Collection of Eye-Popping, Color Block Water Bottles Continuing its Legacy of Bringing Simple Yet Bold Hues to Market

Retrieved on: 
Martedì, Aprile 2, 2024

Nalgene Outdoor, the maker of the “OG” reusable water bottle, the iconic 32-ounce wide mouth, today announces its newest suite of trend-setting colorways, the Color Block collection.

Key Points: 
  • Nalgene Outdoor, the maker of the “OG” reusable water bottle, the iconic 32-ounce wide mouth, today announces its newest suite of trend-setting colorways, the Color Block collection.
  • “In the early 90s just as fitness overtook lifestyle trends, we were the first to offer water bottles in color.
  • Met with such enthusiasm, we’ve continued to expand our color offerings each year, and today our customers look to Nalgene for its savvy and bold choices.
  • Incredibly durable and 100% leakproof, Nalgene water bottles are lightweight, built-to-last, come with a Lifetime Guarantee and are dishwasher safe to keep you on the go!

Journal of Pharmaceutical Analysis (JPA) Studies Find Promising Drug Candidates

Retrieved on: 
Venerdì, Marzo 29, 2024

XI'AN, China, March 29, 2024 /PRNewswire/ -- Understanding the underlying mechanisms of normal and pathological cellular processes is essential for developing new drugs. Fortunately, modern techniques and experimental methods have greatly accelerated progress. The latest issue of JPA features three articles in which candidate compounds for treating complex disorders were successfully identified, alongside their detailed mechanisms of action.

Key Points: 
  • The first study investigated the use of metformin (Met), a drug used to manage type II diabetes, for treating benign prostate hyperplasia (BPH).
  • The article was published in Volume 14, Issue 1 of the journal in January 2024 .
  • Using the Drug Signatures Database, they identified hydralazine (HYD), a potent arterial vasodilator, as a potential UBA52 disruptor.
  • Further studies will hopefully clarify the intricate connections among cellular processes, diseases, and potential drugs, paving the way for precise and efficient therapies.

ICO reprimands London Mayor's Office for Policing and Crime for complaint web form error

Retrieved on: 
Martedì, Aprile 2, 2024

The London Mayor's Office for Policing and Crime (MOPAC), which is responsible for oversight of the Met, had two forms available on its website - one to contact the Victims Commissioner for London and another to raise a complaint about how the Met had handled their original complaint.

Key Points: 
  • The London Mayor's Office for Policing and Crime (MOPAC), which is responsible for oversight of the Met, had two forms available on its website - one to contact the Victims Commissioner for London and another to raise a complaint about how the Met had handled their original complaint.
  • The incident occurred due to an error by Greater London Authority (GLA), which runs the London.gov.uk website, including MOPAC's pages and webforms.
  • Between 11-14 November 2022, a member of GLA intended to give four members of staff at MOPAC permission to access information shared through the web forms.
  • - To report a concern to the ICO telephone our helpline 0303 123 1113 or go to ico.org.uk/concerns.

Bionano Reports Fourth Quarter and Full-Year 2023 Results and Provides Revenue Outlook for 2024

Retrieved on: 
Martedì, Marzo 5, 2024

Total revenue for the fourth quarter of 2023 was $10.7 million, an increase of 30% compared to the fourth quarter of 2022.

Key Points: 
  • Total revenue for the fourth quarter of 2023 was $10.7 million, an increase of 30% compared to the fourth quarter of 2022.
  • GAAP gross margin for the fourth quarter of 2023 was 23%, which was slightly higher than the 22% GAAP gross margin reported for the fourth quarter of 2022.
  • Fourth quarter 2023 GAAP operating expense was $27.4 million, compared to $39.3 million in the fourth quarter of 2022.
  • Fourth quarter 2023 non-GAAP operating expense was $27.3 million, compared to $30.6 million in the fourth quarter of 2022.

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates

Retrieved on: 
Mercoledì, Febbraio 28, 2024

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (Nasdaq/AIM:​HCM; HKEX:​13), the innovative, commercial-stage biopharmaceutical company, today reports its financial results for the year ended December 31, 2023 and provides updates on key clinical and commercial developments. HUTCHMED to host results call and webcasts today at 7:30 a.m. EST / 12:30 p.m. GMT / 8:30 p.m. HKT in English, and at 8:30 a.m. HKT in Chinese (Putonghua) on Thursday, February 29, 2024.

Key Points: 
  • HUTCHMED is committed to progressively embedding sustainability into all aspects of our operations and creating long-term value for our stakeholders.
  • The 2023 Sustainability Report will be published alongside our 2023 Annual Report in April 2024 and will include further information on HUTCHMED sustainability initiatives and their performance.
  • Net Income attributable to HUTCHMED for 2023 was $100.8 million compared to Net Loss attributable to HUTCHMED of $360.8 million in 2022.
  • The net income attributable to HUTCHMED in 2023 was $0.12 per ordinary share / $0.59 per ADS49, compared to net loss attributable to HUTCHMED of $0.43 per ordinary share / $2.13 per ADS in 2022.